FDA approves Prism Pharmaceutical’s treatment for arrhythmia

LENEXA, Kan. The Food and Drug Administration has approved a new drug for treating arrhythmia.

CyDex Pharmaceuticals announced Monday that Prism Pharmaceuticals had won approval for Nexterone (amiodarone IV), a drug developed using CyDex’s Captisol drug-development platform. CyDex said the platform improves the water solubility and stability of active pharmaceutical ingredients. 

“Prism licensed the worldwide rights to an amiodarone formulation developed with Captisol technology from CyDex in early 2006, and we have worked closely with Prism in providing technical support since then,” CyDex president and CEO Theron Odlaug said in a statement.